Combined Treatment
Showing 1 - 25 of >10,000
Combined Hepatocellular Cholangiocarcinoma Trial (gemcitabine ,oxaliplatin,anlotinib,Sintilimab)
Not yet recruiting
- Combined Hepatocellular Cholangiocarcinoma
- gemcitabine ,oxaliplatin,anlotinib,Sintilimab
- (no location specified)
Sep 10, 2023
Extensive Small Cell Lung Cancer Trial in Jinan (Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy)
Recruiting
- Extensive Small Cell Lung Cancer
- Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy
-
Jinan, Shan Dong, ChinaThe First Affiliated Hospital of Shandong First Medical Universi
Nov 6, 2023
Lumbar Spinal Stenosis, Lumbar Instability Trial (CLIF-LP, TLIF)
Not yet recruiting
- Lumbar Spinal Stenosis
- Lumbar Instability
- CLIF-LP
- TLIF
- (no location specified)
Sep 21, 2023
HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor
Not yet recruiting
- HER2-expressing Advanced Solid Tumors
- SHR-A1811 combined with Pyrotinib.
- SHR-A1811 combined with other antitumor therapies
- (no location specified)
Aug 28, 2023
Stroke, Ischemic, Aphasia Trial (active cTBS combined with iTBS, sham cTBS combined with iTBS)
Not yet recruiting
- Stroke, Ischemic
- Aphasia
- active cTBS combined with iTBS
- sham cTBS combined with iTBS
- (no location specified)
Oct 18, 2023
Exotropia, Evaluation of Surgical Techniques in Correcting Exotropia Trial (Evaluation of The Techniques of Lateral Rectus
Not yet recruiting
- Exotropia
- Evaluation of Surgical Techniques in Correcting Exotropia
- Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia
- (no location specified)
Oct 9, 2023
Hepatocellular Carcinoma Trial in Tianjin (HAIC, Adebrelimab, Bevacizumab)
Not yet recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
Jul 27, 2023
Adenocarcinoma of Stomach Trial in Shanghai (Gentuximab Injection, Gentuximab Injection Placebo)
Recruiting
- Adenocarcinoma of Stomach
- Gentuximab Injection
- Gentuximab Injection Placebo
-
Shanghai, Shanghai, ChinaShanghai Dongfang Hospital
Jun 16, 2023
Analgesia Trial in Erzurum (BMI=30; Combined Spinal Epidural Anesthesia, BMI:18,5-24,9; Combined Spinal Epidural Anesthesia)
Recruiting
- Analgesia
- BMI≥30; Combined Spinal Epidural Anesthesia
- BMI:18,5-24,9; Combined Spinal Epidural Anesthesia
-
Erzurum, TurkeyAtaturk University
Aug 29, 2023
Lung Tumors Trial (Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy), Envafolimab combined
Not yet recruiting
- Lung Neoplasms
- Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
- Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
- (no location specified)
Jun 12, 2023
Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)
Not yet recruiting
- Advanced Mucosal Melanoma
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- (no location specified)
Sep 15, 2023
Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)
Not yet recruiting
- Ovarian Cancer Recurrent
- Fluzopril Combined With Apatinib
- (no location specified)
Oct 22, 2023
Precision Medicine for Combined
Recruiting
- Liver Cancer
- phenotyping
-
Créteil, FranceJulien Calderaro
Nov 17, 2023
Gastric Cancer Trial (Disitamab Vedotin combined with Sintilimab)
Not yet recruiting
- Gastric Cancer
- Disitamab Vedotin combined with Sintilimab
- (no location specified)
Jul 2, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC)
Recruiting
- Hepatocellular Carcinoma
- Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Jul 12, 2023
Colorectal Cancer Trial in Tai'an (Tas-102(Suyuan) combined with bevacizumab)
Not yet recruiting
- Colorectal Cancer
- Tas-102(Suyuan) combined with bevacizumab
-
Tai'an, Shandong, ChinaThe Second Affiliated Hospital of Shandong First Medical Univers
Oct 14, 2023
Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Cadonilimab combined Anlotinib
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023
Stroke Trial in Taipei (Combined group, Cognitive group, Rhythmic group)
Not yet recruiting
- Stroke
- Combined group
- +3 more
-
Taipei, TaiwanMackay Memory Hospital
Aug 17, 2023
Rheumatoid Arthritis Trial (Iguratimod combined with Tofacitinib;)
Not yet recruiting
- Rheumatoid Arthritis
- Iguratimod combined with Tofacitinib;
- (no location specified)
Mar 26, 2023
Schizophrenia Negative Type Trial in Tianjin (tDCS active stimulation combined with rTMS sham stimulation, rTMS active
Enrolling by invitation
- Schizophrenia Negative Type
- tDCS active stimulation combined with rTMS sham stimulation
- +3 more
-
Tianjin, Tianjin, ChinaJie Li
Jan 14, 2023
Spine Degeneration, Spine Fusion, Frailty Syndrome Trial (Pre-operative risk assessment combined with targeted intervention)
Not yet recruiting
- Spine Degeneration
- +2 more
- Pre-operative risk assessment combined with targeted intervention
- (no location specified)
Nov 14, 2023
Segmental Resection Combined With DEP Regimen for EBV-HLH
Not yet recruiting
- Hemophagocytic Lymphohistiocytosis
- +2 more
- Segmental bowel resection combined with the DEP regimen
-
Beijing, Beijing, ChinaZhao Wang
Nov 9, 2023
Nasopharyngeal Carcinoma Trial (Envafolimab and recombinant human endostatin combined with chemoradiotherapy)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Envafolimab and recombinant human endostatin combined with chemoradiotherapy
- (no location specified)
Sep 23, 2023
Combined Arteriovenous Noninvasive Oximetry
Not yet recruiting
- Oxygen Consumption
- Finger pulse oximetry probe
- Transreflectance oximetry probe
-
Madison, WisconsinUniversity of Wisconsin
Oct 2, 2023